FDA delays action date for Theratechnologies
July 20, 2010 by leonardzehr · Leave a Comment
Theratechnologies (TSX:TH) expects to have an official response from the FDA in the fourth quarter this year about its new drug application for its tesamorelin, a treatment for excess abdominal fat in HIV-infected patients with lipodystrophy. The FDA had originally targeted July 27 to complete its review. “The FDA has indicated that the review is [...]
Listen to BioTuesdays 
